NanoRepro AG (ETR:NN6)
1.730
-0.070 (-3.89%)
Oct 15, 2026, 5:35 PM CET
NanoRepro AG Revenue
In the year 2025, NanoRepro AG had annual revenue of 4.34M EUR, down -3.02%. NanoRepro AG had revenue of 1.91M in the half year ending December 31, 2025, with 6.58% growth. That makes NanoRepro AG the 40,044th largest company in the world by revenue and 546th in Germany.
Revenue
4.34M
Revenue Growth
-3.02%
P/S Ratio
5.24
Revenue / Employee
197.08K
Employees
22
Market Cap
21.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.34M | -134.88K | -3.02% |
| Dec 31, 2024 | 4.47M | 1.29M | 40.42% |
| Dec 31, 2023 | 3.18M | -35.30M | -91.73% |
| Dec 31, 2022 | 38.49M | -124.23M | -76.35% |
| Dec 31, 2021 | 162.72M | 145.79M | 861.19% |
| Dec 31, 2020 | 16.93M | 15.71M | 1,289.58% |
| Dec 31, 2019 | 1.22M | -1.09M | -47.21% |
| Dec 31, 2018 | 2.31M | 648.55K | 39.09% |
| Dec 31, 2017 | 1.66M | 119.99K | 7.79% |
| Dec 31, 2016 | 1.54M | 1.09M | 241.98% |
| Dec 31, 2015 | 450.12K | -591.59K | -56.79% |
| Dec 31, 2013 | 1.04M | 1.04M | 111,312.51% |
| Dec 31, 2012 | 935.00 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Maternus-Kliniken Aktiengesellschaft | 119.35M |
| FamiCord AG | 87.78M |
| Biofrontera AG | 15.97M |
| MeVis Medical Solutions AG | 15.48M |
NanoRepro AG News
- 10 days ago - Original-Research: NanoRepro AG (von NuWays AG): BUY - Finanz Nachrichten
- 10 days ago - NanoRepro gains majority in Deutsche Kosmetikwerke: NanoRepro gains majority in Deutsche Kosmetikwerke ... - Finanz Nachrichten
- 10 days ago - NanoRepro gains majority in Deutsche Kosmetikwerke - Wallstreet:Online
- 5 weeks ago - New revenue guidance reinforces growth trajectory; chg. est.: NanoRepro's new revenue guidance implies ... - Finanz Nachrichten
- 5 weeks ago - New revenue guidance reinforces growth trajectory; chg. est. - Wallstreet:Online
- 6 weeks ago - Nutritional elixirs as third consolidated pillar for NanoRepro - Wallstreet:Online
- 2 months ago - Preliminary H1'26 revenue beats expectations; chg. est. & PT: NanoRepro's preliminary H1 26 sales ... - Finanz Nachrichten
- 2 months ago - Preliminary H1'26 revenue beats expectations; chg. est. & PT - Wallstreet:Online